Mefic

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mefic

Property Description
Active ingredient Mefenamic Acid
Form Capsule, Tablet, Oral Suspension
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common purpose Pain management, Inflammation, Fever reduction
Origin Synthetic compound

What Type of Medicine is Mefic and Its Classification?

Mefic is a prescription-only medicinal product containing the active ingredient Mefenamic Acid (INN), a synthetic compound. It is fundamentally classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). Mefenamic Acid is chemically defined as an Anthranilic Acid derivative, which places it within the specific Fenamate group of NSAIDs. This classification affirms its established pharmacological action in addressing symptoms associated with inflammatory pathways. The original branded formulation, Ponstel, distinguished Mefenamic Acid when first introduced, underscoring its established medical presence as a reliable option for symptom management.


Mefic's Composition, Form, and General Purpose

The drug is a single-ingredient product designed for Oral administration, and it is typically supplied as Capsules or Tablets, with an Oral Suspension also available, which often targets pediatric patients or those requiring ease of swallowing. Mefic's overall purpose is to provide relief by functioning as an Analgesic, an Anti-inflammatory agent, and an Antipyretic. These agents work by blocking the chemical signals that promote pain and heat generation. Therefore, Mefic addresses pain, reduces inflammation, and helps lower an elevated body temperature, particularly useful in general scenarios like controlling discomfort related to minor injuries or temporary inflammatory conditions.


How Mefic Compares to Other Pain Relievers

Mefic belongs to the same broad class as other common pain relievers—the NSAIDs—meaning its core function relies on the inhibition of prostaglandin synthesis. This distinguishes its action from non-NSAID analgesics that target different neurological pathways. The compound's structural classification as a Fenamate (an Anthranilic Acid derivative) is its differentiating feature within the NSAID subclass, providing a chemically distinct alternative to manage inflammatory symptoms compared to those in the Propionic Acid subclass, such as ibuprofen.

Regulatory References

  1. Mefenamic Acid: MedlinePlus Drug Information
  2. The potential and promise of mefenamic acid - PubMed

What side effects are possible with Mefic?

Mefic: Possible Side Effects and Safety Information

Official regulatory documents define the safety profile of Mefic based on documented adverse reactions and necessary restrictions. The information is categorized primarily by the System Organ Class affected and the frequency of occurrence, following standards set by bodies like the FDA and EMA.

Serious and Clinically Significant Risks

Mefic is associated with the potential for serious adverse reactions, which, by regulatory definition, are those events that are life-threatening, result in death, require hospitalization, or cause persistent/significant disability. Key safety warnings include the risk of:

  • Serious Gastrointestinal (GI) Events: Including bleeding, ulceration, and perforation of the stomach or intestines.
  • Serious Skin Reactions: Such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).
  • Cardiovascular Thrombotic Events: Including myocardial infarction and stroke.
  • Renal Toxicity: Risk of new-onset or worsening kidney dysfunction, which may lead to renal failure.

Contraindications and Restrictions

The medicine is contraindicated (must not be used) in patients with a known history of hypersensitivity or allergic-type reactions to Mefic, aspirin, or other non-steroidal anti-inflammatory drugs (NSAIDs). Use is also restricted in patients with pre-existing renal disease or significantly impaired renal function. Concomitant use with aspirin is generally advised against due to an increased risk of serious GI events.

General Adverse Reactions

Adverse reactions that are commonly documented include events affecting the Gastrointestinal System (e.g., diarrhea, nausea, abdominal discomfort) and the Nervous System (e.g., dizziness, headache). The full spectrum of documented adverse events is categorized by frequency, ranging from 'Very Common' (affecting 10% or more of patients) to 'Rare' (less than 1 in 10,000 patients).

Regular safety monitoring is mandated in official labels to track for signs of serious reactions, especially in special populations or those with specific underlying health conditions.

Overdose and Emergency Response

Overdose and When to Seek Help

Officially Documented Manifestations

Acute overdose of Mefic, containing Mefenamic Acid, primarily presents with signs affecting the central nervous system (CNS) and gastrointestinal (GI) systems, as described in regulatory labeling. Documented manifestations include seizures (convulsions), lethargy, and potentially coma. GI effects reported are commonly nausea, vomiting, and epigastric pain. There is also an officially stated risk of tinnitus (ringing in the ears).

Severe and Life-Threatening Outcomes

The official overdose profile emphasizes risks for severe physiological complications. These include acute renal failure and gastrointestinal bleeding, which can be life-threatening. Regulatory documents also cite the potential for cardiovascular collapse and a fatal outcome in cases of massive or severe acute ingestion. Population-specific notes indicate a higher risk of acute renal failure in patients with pre-existing renal impairment and a potential for higher CNS toxicity in adolescents.

Mandated Emergency Action and Management

Regulatory authorities require individuals to seek immediate medical attention and contact a Poison Control Center if an overdose is suspected or confirmed. Urgent medical help is specifically mandated if the person is seizing, cannot be awakened, or has collapsed. The official labeling states that no specific antidote is known. Management, therefore, is focused on symptomatic and supportive treatment, maintaining vital functions, and includes consideration for procedures like gastric lavage and activated charcoal if performed early. Hospital monitoring is required for all confirmed overdose cases.

Therapeutic Uses of Mefic

What Mefic Treats: Main Uses and Benefits

Mefic is relevant in contexts marked by increased discomfort or tension and may be part of symptomatic management. It is applied in clinical settings that involve acute or unstable symptom patterns to help moderate the intensity of distressing manifestations and ease the overall symptom burden when symptoms interfere with daily stability.

Quick Fact: Relief for Acute Symptom Clusters

The therapeutic use of this medication involves managing discomfort and addressing acute symptom patterns.

Mefic is commonly used across conditions characterized by periods of heightened symptoms and may be appropriate when symptoms become more noticeable. This includes addressing symptoms related to physical discomfort and those that create noticeable functional strain. It is generally used when short-term symptomatic assistance is needed and contributes to improved comfort during such periods.

The medication is relevant for easing symptoms that create noticeable functional strain and interfere with daily comfort. It provides support that helps ease the overall symptom burden, assists with maintaining functional stability, and offers supportive relief during difficult, short-term episodes.

Regulatory References

  1. NIH DailyMed overview of Indications

Eligibility and Restrictions for Use

Eligibility for Mifepristone (Mefic)

Mifepristone is officially indicated for the medical termination of an intrauterine pregnancy through 70 days (10 weeks) of gestation. Use beyond this gestational age is not covered by the current regulatory indication.

Contraindications: Who Must Not Use This Medicine

The medicine is strictly contraindicated for use in patients with the following conditions, as these may lead to serious complications:

  • A confirmed or suspected ectopic pregnancy.
  • Chronic adrenal failure or current use of long-term systemic corticosteroid therapy.
  • Hemorrhagic disorders or concurrent use of anticoagulant (blood thinning) therapy.
  • A history of hypersensitivity or allergic reaction to mifepristone, misoprostol, or other prostaglandins.
  • An inherited porphyria.
  • An intrauterine device (IUD) in place, which must be removed before treatment begins.

Eligibility-Related Restrictions

The drug is subject to the Mifepristone REMS Program, which restricts its prescribing and dispensing. Patients must review and sign a Patient Agreement Form with a certified healthcare provider to acknowledge the risks and confirm they meet the eligibility criteria.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Mefenamic Acid (Mefic) documents several categories of interactions, primarily related to its Nonsteroidal Anti-inflammatory Drug (NSAID) class effects.

Classification Official Interaction Statement Constraint / Requirement
Contraindicated Co-administration with other systemic NSAIDs (including COX-2 inhibitors) is prohibited. Avoid all combined use due to additive GI risk.
Use is contraindicated for peri-operative pain after Coronary Artery Bypass Graft (CABG) surgery. Avoid use in this specific procedural context.
Pharmacodynamic Oral Anticoagulants (e.g., Warfarin), Antiplatelet agents, and SSRIs Increases the documented risk of serious gastrointestinal bleeding.
Pharmacokinetic (PK) Lithium and Methotrexate Reduces their renal clearance, leading to elevated plasma levels and risk of toxicity.
Magnesium-containing Antacids Significantly increases the rate and extent of Mefenamic Acid absorption.
Timing-Specific Mifepristone Mefenamic Acid should not be administered for 8 to 12 days following Mifepristone.
Population-Specific Elderly/Volume-Depleted Patients with Diuretics/ACE Inhibitors Heightened risk of renal function deterioration (nephrotoxicity).

Combinations with Diuretics and medicines affecting the Renin-Angiotensin System (ACE Inhibitors/ARBs) may diminish their antihypertensive and diuretic efficacy. Furthermore, Alcohol is noted to increase the risk of serious GI adverse events. This profile defines constraints based on potential for increased toxicity, loss of efficacy, and specific procedural and timing requirements.

Mechanism of Action

Mefic is an antagonist of the interleukin-17A receptor ( IL-17 RA), a transmembrane protein critical for T H17-mediated inflammatory signaling. The drug binds selectively to IL-17 RA on target cells, preventing the attachment of the natural ligand, interleukin-17A ( IL-17 A). Antagonism of IL-17 A binding modulates the IL-17 signaling pathway and reduces the subsequent transcription and translation of pro-inflammatory chemokines and cytokines, including IL-6, IL-8, and TNF-alpha. This mechanistic cascade regulates the localized inflammatory response and influences catabolic signaling within articular tissues. The selective IL-17 RA antagonism limits the modulation of other immune pathways, resulting in a sustained neutralization of IL-17 pathway signaling, which affects downstream cellular responses.

Dosage and Administration Information

Administration Guidelines for Mefic

Mefic (Mefenamic Acid) is administered by the oral route using available forms such as capsules, tablets, or oral suspension. Use of the medicine is characterized by a core principle: employing the lowest effective dose for the shortest duration necessary.


Dosing Schedule and Duration

The standard adult regimen begins with a 500 mg initial dose followed by 250 mg maintenance doses. This maintenance dose is taken every 6 hours as needed; alternatively, an adult dose of 500 mg three times daily is used in certain protocols.

Treatment duration is subject to specific limits. For general acute use, therapy must not exceed one week (7 days). For use related to menstrual pain (primary dysmenorrhea), the treatment duration should not exceed 2 to 3 days, with administration beginning at the onset of bleeding or associated symptoms.


Procedural and Population Rules

Administration Scope Instruction
Timing in relation to meals Recommended to be taken with food or milk to aid proper intake.
Age-group rules Usage in children under 14 years is restricted in some labeling; other guidelines specify a pediatric dose up to 25 mg/kg daily in divided doses for children older than 6 months.
Missed-dose protocol If a dose is missed, it should be taken as soon as remembered. If close to the next scheduled dose, the missed dose is skipped. Do not double the dose.

These instructions define a standardized protocol for use, where Mefic is administered in a time-constrained, divided-dose pattern.

Recent Clinical Evidence

Research evidence / Overview of Studies for Mefic (Mefenamic Acid)

This section outlines the types of official research that have been conducted to evaluate Mefic, focusing on what studies have explored and what remains to be fully established, without offering clinical guidance. The evidence base primarily comes from controlled clinical trials and regulatory reviews.


Evidence for use in Primary Dysmenorrhea (Menstrual Cramps)

Research for Mefic in the context of primary dysmenorrhea, or menstrual cramps, has largely utilized short-term, randomized controlled trials (RCTs). These studies were applied in research contexts involving fluctuating or unstable symptoms. Researchers measured patient-reported outcomes describing perceived discomfort, such as pain intensity scores.

Research reports patterns observed in studies related to outcomes linked to inflammatory or irritative states. The evidence contributes to the body of research relevant to this use. However, because Mefic is only studied during the acute period (typically two to three days each cycle), there is limited information for long-term outcomes regarding the repeated, periodic use of this medication over many years.


Evidence for use in Mild to Moderate Acute Pain

Mefic was evaluated in research exploring short-term symptom changes associated with conditions involving periods of heightened symptoms, such as pain following a dental procedure or injury. Studies utilized randomized trial designs. Research explored outcomes related to physical discomfort and examined symptom intensity or variability over defined time intervals.

Findings help contextualize how patients reported their experience related to acute pain during the observation period defined by the study. A key constraint is that regulatory bodies restrict the study duration for acute pain to a maximum of seven days. Because of this, studies focusing on acute pain are strictly very short-term, and long-term effects are not fully established for continuous daily use beyond one week.


Key Research Limitations and Areas of Uncertainty

The research landscape highlights several constraints. A major limitation is that the follow-up durations were limited across the core indications due to regulatory mandates, meaning that the long-term effects are not fully established. For chronic conditions, such as arthritis, the research focuses on short periods due to class-wide safety considerations that restrict continuous use.

Evidence quality varies across studies for the secondary indications, and findings were mixed in some comparisons to other analgesics. Research provides context but not individual predictions, and the study results reflect the specific conditions under which they were conducted, which may not apply universally.

Key Studies & References

  1. Mefenamic Acid Prescribing Information / Drug Label (General and Acute Indications)

Frequently Asked Questions (FAQ)

Common questions about Mefic (FAQ)


Q: What are the most common side effects people report when taking Mefic?

According to the official product information, some of the most commonly reported effects include diarrhea, nausea, and general abdominal discomfort. Central nervous system effects such as headache and dizziness are also frequently noted in the safety documentation.


Q: Can Mefic be used by older adults?

Official documentation indicates that while older adults may use Mefic, they are generally at a higher risk for experiencing serious adverse events. This includes a heightened potential for severe gastrointestinal issues and effects on the heart or kidneys.


Q: What types of food or drinks should be avoided while taking Mefic?

Regulatory documents describe Mefic use with food or milk to facilitate proper intake. It is specifically noted that consuming alcohol alongside the medication may significantly increase the risk of serious gastrointestinal adverse events.


Q: Does Mefic interact with supplements like vitamins or herbal products?

Official interaction statements warn of potential reactions with certain substances, including specific herbal products. Official guidance emphasizes the importance of reviewing all supplements, vitamins, and herbal products with a healthcare provider.


Q: Is it normal to feel a bit tired when starting Mefic?

Official product information lists central nervous system effects such as drowsiness and fatigue (tiredness) as possible side effects. These effects are documented in official safety information.


Q: Can Mefic affect mood or mental state?

Regulatory data indicates that Mefic may affect mental state for some individuals. Documented, though less common, psychiatric adverse reactions include feelings of anxiety, confusion, and depression.


Q: What is the purpose of the black box warning on Mefic's official label?

The highest level of regulatory warning, often referred to as a Boxed Warning, is used to highlight serious risks associated with the medicine. For Mefic, this warning covers the potential for serious cardiovascular thrombotic events (like heart attack or stroke) and serious gastrointestinal adverse events (like bleeding or ulcers).


Q: Does taking Mefic require routine blood monitoring?

Official documents suggest that for individuals on long-term therapy, physicians may periodically order laboratory tests. This monitoring may include checking a Complete Blood Count (CBC) and a chemistry profile.


Q: Is Mefic associated with sleep changes (insomnia or increased sleepiness)?

Official adverse reaction data reports both drowsiness (increased sleepiness) as a common central nervous system effect and insomnia (trouble sleeping) as a reported psychiatric effect. This indicates the drug may affect sleep patterns.


Q: Can Mefic affect driving or operating machinery?

The official patient leaflet contains guidance regarding activities that require attention. It states that because Mefic can cause drowsiness, dizziness, or affect vision, the guidance advises that activities requiring full attention, such as driving or operating machinery, should be avoided if these effects are experienced.


Q: What did the main clinical trials for Mefic show?

Studies have examined efficacy for acute pain, such as those using a single 500 mg dose. Evidence indicates that approximately 48% of participants experienced a good level of pain relief over the initial four to six hours compared to a placebo group.


Q: Why is Mefic listed as a high-risk drug for certain groups?

Mefic's classification is linked to specific regulatory warnings about the potential for serious adverse events in susceptible populations. These risks include serious gastrointestinal issues, cardiovascular thrombotic events, and renal toxicity.


Q: Are there generic versions of Mefic available internationally?

The active ingredient in Mefic is Mefenamic Acid, which is widely available as a generic version. This generic drug is available in the US market and globally, providing alternatives for the branded formulation.


Q: What is the mechanism of action of Mefic described in official documents?

According to official documents, Mefic is a non-steroidal anti-inflammatory drug (NSAID) that works by modulating the body's chemical signals. Specifically, its mechanism involves inhibiting the production of prostaglandin synthesis by binding to the COX-1 and COX-2 receptors.


Q: How long does Mefic typically take to start working?

Clinical trial research indicates that the effects of Mefic can be measured over the initial period following administration. Studies suggest that pain relief is typically tracked over the initial four to six hours after taking a single dose.


Q: Is Mefic a controlled substance or addictive?

Official drug classifications confirm that Mefic is not a controlled medication. Therefore, it is not classified as a scheduled or potentially addictive drug by regulatory agencies.


Q: Can Mefic be used during pregnancy or while breastfeeding?

Regulatory information states that Mefic use is contraindicated during the last trimester of pregnancy due to the potential for fetal harm. It is also generally not recommended during breastfeeding as trace amounts may enter breast milk.


Q: Why does Mefic have a warning about liver health?

Official regulatory information notes the possibility of liver problems (hepatotoxicity) with the drug. Official guidance indicates that Mefic is typically discontinued if certain liver tests persist or worsen.


Q: Is it true that Mefic causes weight changes for some people?

While general weight changes are not listed as a common effect, official warnings related to cardiovascular risk do note certain symptoms. Unusual weight gain is listed among the possible symptoms associated with the risk of heart failure.


Q: How quickly does Mefic leave the body?

According to official pharmacokinetic data, the drug has a relatively rapid clearance. Mefic has a short half-life of approximately 2 hours.


Q: What should I do if a side effect of Mefic seems severe?

Official safety guidance indicates that in the event of a severe or serious adverse reaction, the medicine is typically stopped immediately. The protocol advises that emergency medical help should then be sought.


Q: Why do some people say Mefic didn't work for them?

Studies and official information indicate that the effectiveness of Mefic can vary among different individuals. The research evidence summary already notes that findings were mixed in some comparisons to other treatments.


Q: Are there specific tests I need before starting Mefic?

Due to known risks, a healthcare provider may perform a pre-treatment evaluation before starting the medicine. This is particularly relevant for individuals with pre-existing conditions like kidney or liver problems to determine appropriate use.


Q: What should I do if I feel Mefic is not working for me?

Official patient guidance suggests that symptoms should show improvement within a few days when used for menstrual pain. The protocol states that if symptoms persist after the maximum labeled duration (typically 7 days), consulting a healthcare provider is the appropriate next step.


Q: Can Mefic affect fertility?

Official warnings state that use of NSAIDs, including Mefic, may impair female fertility. The official warning indicates that Mefic is generally not advised for use in women actively attempting to conceive.


Q: What information is legally required to be on the Mefic leaflet?

Official regulatory requirements mandate that the patient leaflet (or Medication Guide) includes several core information sections. These typically cover Uses, Contraindications (who must not use it), Warnings/Precautions, Side Effects, and Dosing/Administration details.

How should Mefic be stored and disposed of?

How to Store and Dispose of Mefic

Official regulatory labeling specifies mandatory requirements for the storage and disposal of Mefic (Mefenamic Acid).

Storage Requirements

Storage Condition Requirement
Temperature Store at temperatures not exceeding 30 C (86 F), or 25 C (77 F), as specified on the label.
Protection Keep the container tightly closed and store with protection from light and moisture.
Child Safety Must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Mefic must be discarded according to official waste protocols. The FDA recommends using a drug take-back program. Where such programs are unavailable and the medicine is not on the flush list, it may be mixed with an undesirable substance, placed in a sealed bag, and disposed of in household trash. Certain regions prohibit disposal via wastewater or household waste, requiring consultation with a pharmacist.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mefic found in:

A-Z Index: